📖
The effect of lenvatinib and pembrolizumab on thyroid cancer refractory to iodine 131I simulated by mathematical modeling
Jairo Gomes Da Silva, Izabel Cristina Rodrigues Da Silva, Mostafa Adimy, Paulo Fernando de Arruda Mancera

The effect of lenvatinib and pembrolizumab on thyroid cancer refractory to iodine 131I simulated by mathematical modeling

Science & Mathematics Published 2022 Verification Pending

Overview & Synopsis

Immunotherapy and targeted therapy are alternative treatments to differentiated thyroid cancer (DTC), which is usually treated with surgery and radioactive iodine. However, in advanced thyroid carcinomas, molecular alterations can cause a progressive loss of iodine sensitivity, thereby making cancer resistant to radioactive iodine-refractory (RAIR). In the treatment of cancer, tyrosine kinase inhibitors are administered to prevent the growth of cancer cells. One such inhibitor, lenvatinib, forms a targeted therapy for RAIR-DTC, while the immunotherapeutic pembrolizumab, a humanized antibody, prevents the binding of programmed cell death ligand 1 (PD-L1) to the PD-1 receptor. As one of the first studies on treatments for thyroid cancer with mathematical model involving immunotherapy and targeted therapy, we developed an ordinary differential system and tested variables such as concentration of lenvatinib and pembrolizumab, total cancer cells, and number of immune cells (i.e., T cells and natural killer cells). Analyzing local and global stability and the simulated action of drugs in patients with RAIR-DTC, revealed the combined effect of the targeted therapy with pembrolizumab. The scenarios obtained favor the combined therapy as the best treatment option, given its unrivaled ability to boost the immune system’s rate of eliminating tumor cells.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title The effect of lenvatinib and pembrolizumab on thyroid cancer refractory to iodine 131I simulated by mathematical modeling
Author / Organization Jairo Gomes Da Silva, Izabel Cristina Rodrigues Da Silva, Mostafa Adimy, Paulo Fernando de Arruda Mancera
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2022
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-142861
Original Source Link Visit Source Page on hal.science »